NRXPWNCM

NRx Pharmaceuticals, Inc.

-82.7% · 90d

$0.01

-0.00 (-11.27%)

News

No News Yet

Press releases and SEC filings for NRXPW will appear here as they are published.

Check back later for updates

Key Data

Market Cap—

Open$0.16

Prev Close$0.01

Day Range$0.00 – $0.01

52W Range$0.00 – $0.01

Volume120,310

P/E (TTM)—

EPS$-6.25

Dividend Yield—

Beta1.83

About

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

29 employees

www.nrxpharma.com

Top Institutional Holders

As of 2025-12-31 · prior 2025-09-30

Anson Funds Management LP$8.2M

3,043,957 sh+50.3%

COMMONWEALTH EQUITY SERVICES, LLC$993,570

366,631 sh● NEW

UBS Group AG$9,588

3,538 sh-97.7%

Bleakley Financial Group, LLC$317,623

117,204 sh● NEW

AdvisorShares Investments LLC$888,891

328,004 sh-4.1%

See all holders →

Quarterly Financials

09/25

Revenue Net Income